Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells $37,335.55 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. The trade was a 2.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $3.09 on Friday. Voyager Therapeutics, Inc. has a 52 week low of $2.95 and a 52 week high of $9.55. The firm has a 50-day moving average price of $4.30 and a two-hundred day moving average price of $5.55. The firm has a market cap of $170.59 million, a price-to-earnings ratio of 4.35 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same quarter last year, the business posted $1.25 earnings per share. As a group, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP increased its holdings in Voyager Therapeutics by 151.0% during the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after buying an additional 740,000 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after acquiring an additional 278,700 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $746,000. Finally, ADAR1 Capital Management LLC lifted its stake in Voyager Therapeutics by 212.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company’s stock valued at $719,000 after purchasing an additional 86,158 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

VYGR has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $13.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.